IP Library Granted Patent US 6,903,199
Granted Patent B2
US 6,903,199 · App. 10/398,065 · Granted Jun 7, 2005

Crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof

Assignee: LG Life Sciences Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,903,199
App. No.
10/398,065
Granted
Jun 7, 2005
Kind
B2
Abstract

The present invention relates to water-insoluble, crosslinked amide derivatives of hyaluronic acid and manufacturing method thereof, where the amide derivatives of hyaluronic acid are characterized by crosslinking, of polymer or oligomer having two or more amine groups, with hyaluronic acid or its hyaluronate salts through amidation reaction. The water-insoluble, crosslinked amide derivatives of hyaluronic acid according to the present invention may be diversely used for prevention of adhesion after surgical operation, correction of facial wrinkles, dermal augmentation, tissue engineering, osteoarthritic viscosupplement etc.

Claims (19)

1. A method for manufacturing water-insoluble, hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer selected from the group consisting of chitosan, deacetylated hyaluronic acid and deacetylated hyaluronate salts, having two or more reactable amine groups which can accept protons, said method comprising the step of: reacting said polymer or oligomer with hyaluronic acid or its hyaluronate salts through an amidation reaction in the presence of a carboxyl group activating agent and said activating agent may optionally include an auxiliary agent.

2. The method of claim 1 , wherein the polymer or oligomer having amine groups which can accept protons is selected such that it is positively charged under acidic or neutral conditions and wherein the amidation reaction is promoted by the electrostatic attraction between the positively charged amine groups of said polymer or oligomer and the carboxyl groups of said hyaluronic acid or hyaluronate salts.

3. The method of claim 2 , wherein said amidation reaction is carried out under acidic or neutral conditions.

4. The method of claim 1 or 2 , wherein the ratio of the carboxyl groups of the hyaluronic acid or hyaluronate salts versus the amine groups of the polycationic polymer or oligomer is in the range of 1:0.01 to 100 in the reaction mixture.

5. The method of claim 1 or 2 , wherein the molecular weight of hyaluronic acid or hyaluronate salts is in the range of 10,000 to 10,000,000 and the concentration of those is in the range of 0.01 mg/ml to 100 mg/ml.

6. The method of claim 1 , wherein carbodiimide is being used as carboxyl group activating agent.

7. The method of claim 6 , wherein said carbodiimide is 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) while N-hydroxysuccinimide(NHS) is added optionally as an auxiliary agent to the amidation reaction.

8. The method of claim 6 , wherein said carbodiimide is selected from the group consisting of 1-alkyl-3-(3-dimethylaminopropyl) carbodiimides having a structure similar to EDC, 1-ethyl-3-(3-(trimethylammonio)propyl)carbodiimide (ETC) or 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide (CMC) while a compound selected from the group consisting of N-hydroxysuccinimide (NHS), 1-hydroxybenzotriazole (HOBt), 3,4-dihydro-3-hydroxy-4-oxy-1,2,3-benzotriazine (HOOBt), 1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysulfosuccinimide (Sulfo-NHS) is added optionally as auxiliary agent to the amidation reaction.

9. The method of claim 7 , wherein said EDC is added in the range of 0.0001 to 100 mg/ml and said NHS is added in the range of 0-100 mg/ml.

10. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 1 .

11. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 2 .

12. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 4 .

13. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 3 .

14. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 5 .

15. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 6 .

16. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 7 .

17. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 8 .

18. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer manufactured by the method of claim 9 .

19. The water-insoluble hyaluronic acid or hyaluronate salts crosslinked with a polymer or oligomer of claim 10 , wherein those have form of gel, membrane, bead or mesh.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2003
From: MOON, TAE-SEOK; LEE, JAE-YOUNG; KIM, JIN-HOON; HAN , KYU-BOEM
To: LG LIFE SCIENCES LTD.
Reel/Frame 013580/0525 →
Priority Claims (1)
KR 2000-59443 · Oct 10, 2000 · national
Continuity (1)
Related Publication 20040014960A1 · Jan 22, 2004